Veradermics is trading 4.5% up now at $117.90, with no new company-specific announcement, earnings release, FDA action, or other definitive September 22, 2026 catalyst identified.

  • The move follows strong recent sessions and ongoing investor attention around VDPHL01 clinical milestones and bullish analyst targets, including expectations for upcoming data.
  • Available coverage does not establish that those earlier developments directly caused the current move.